🇺🇸#INCY #отчетность
Incyte Q2
Non-GAAP EPS of $0.80 beats by $0.06;
GAAP EPS of $0.67 beats by $0.12.
Revenue of $705.71M (+2.6% Y/Y) beats by $18.76M.
Jakafi (ruxolitinib) revenues of $529M in Q2 2021 (+12% vs Q2 2020)
FY21 Outlook: Jakafi (ruxolitinib) revenues of $2,125M - $2,170M from prior uidance of $2,125M - $2,20M.